Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. - Wikidata - awgldk - TriplyDB

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

http://www.wikidata.org/entity/Q37263146

about

Deferasirox for managing iron overload in people with myelodysplastic syndrome Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy The Danish National Acute Leukemia Registry Refractory anemia with ring sideroblasts and RARS with thrombocytosis Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes The European Hematology Association Roadmap for European Hematology Research: a consensus document Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.The indications for allogeneic stem cell transplantation in myeloid malignancies.Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models.Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort.[Myelodysplastic syndromes].Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast.Clinical and genetic predictors of prognosis in myelodysplastic syndromes.Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood Myelodysplastic syndromes: diagnosis, prognosis, and treatment.The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups.Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.Myelodysplastic syndromes, version 2.2015 Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes

P2860

Q24193067-26B95116-B390-4386-8A1D-B1490F51ECF8 Q26748281-495C986E-1567-4CE6-AD21-D0F6310D6208 Q27010653-BD010EC1-8C88-49DA-9476-DE1E492C7239 Q28075468-4CDD41B2-70B3-4E34-A4DC-7865DD979C95 Q28083238-7E3F9844-6179-403C-A5FF-F265FCE7457C Q28387115-93FE12D0-38A7-4785-8E66-0495B1CA0A19 Q28392451-D4EC652D-5E11-462E-96F8-A95FFFB4F194 Q28830861-C4C9152A-4BD6-403C-9E32-CC18CBB09F5E Q30235355-5FD86AD2-B4F2-4F8B-A0DD-295EAD3713DC Q30240190-9197E25E-CCF8-4F0A-A4D3-98B37F2FD2BD Q30249108-3FE50467-9C16-4A13-849A-8C6D7282C1B1 Q30316611-28C2D7FA-8958-4BD7-9EE5-F41138AE3CFA Q31054529-07BEF19E-9D0D-4CE3-8E7E-0C02696E71E1 Q33416891-16773E12-4E6A-44EB-BF21-C4E505548D84 Q33420574-056356C2-AB7B-4C82-BA1E-EF48BD682CE6 Q33434768-5B84A998-7FDB-4D67-B79C-9A7CEECEDCC7 Q33651786-60226EC1-B3E0-4DDB-85C0-4C1011C4B8D9 Q33695906-5D41A8A9-D4D7-4A97-9BAA-3E076B500D55 Q33709905-5B387A6D-A44A-4147-95FF-8E196FA60F78 Q33829778-0C5CC2FB-BE36-459B-8FF9-418812E69BA1 Q33841401-092B1454-2A24-49EC-BDF2-B298F84DCC79 Q33914183-9EDAEDF9-D4BF-4F73-878F-794482330FB6 Q34106883-D829F687-F2E4-4ABC-B751-3BB3E0FAC045 Q34217884-FE2F1609-F100-4804-B188-4D33EF1F7E14 Q34389508-EDB59D16-8B6B-4F51-AFF5-CCD4F6B74636 Q34520113-BE7768AA-16B2-4BF8-953D-2C5568F54FDE Q34783754-AE578E57-5B09-4643-BD8D-C5FE1E7E72A3 Q35143275-44C69A38-4FBC-4381-B04A-116B23632006 Q35156907-A181340B-DAC6-4B8A-8F48-A25A514F2A17 Q35638905-07F264DD-3861-4E7B-951D-D80809A5C042 Q35917455-E3EB034A-00C8-4446-AE44-604E16529698 Q35925679-561B7911-2BBB-4F1C-B7A4-4970F73CA57A Q36095679-A5C47F99-0C69-4587-9897-E129BAF4A719 Q36107268-4BDA9868-BF1C-4265-9EFA-71C31A1B5731 Q36158816-63F2B1B1-5A77-42C4-80E5-AFC6C1131C1D Q36185741-43596986-4CE4-44CC-9614-6A4679D521B7 Q36290615-B3A98D04-29AC-41F6-B9D3-3032B417D534 Q36416338-7BD80D12-B117-4465-98F6-FD2C38183C1C Q36544042-66DBCFB2-05CD-403B-9271-9156CDB572EC Q36846660-826C37D9-1973-4C5C-BD29-91A494618382

P2860

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

http://www.wikidata.org/entity/Q37263146

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@en

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@nl

type

label

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@en

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@nl

prefLabel

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@en

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@nl

P1433

Q37263146-A80E1906-6283-48A9-8215-CEC050B2C1B5

P1476

Q37263146-BF5BB406-2F55-43D9-96BD-52A3E1272A13

P2093

Q37263146-0E9EC709-40A0-48C9-8F89-D6F787CC8288

Q37263146-1284B776-BE99-4D07-AC51-9AFB4429E208

Q37263146-2DC0DA8E-5F21-42A8-A0F8-B1AFA67507DB

Q37263146-37AC36B8-BA0D-4073-BE60-172CE10FFB79

Q37263146-3FEFB3C8-8D9D-4D36-AA82-B68C9D556202

Q37263146-48FD9297-A179-401E-8B3E-A77B183900E6

Q37263146-633317A4-2976-440C-B71F-27264B19CE56

Q37263146-6F676337-58FB-44CF-BD1E-086CA2FF38C2

Q37263146-722FB388-1576-488E-9CBE-91E1C0BCC1ED

Q37263146-7E8C3894-11AF-40A0-A8E3-A8675714CBBC

P2860

Q37263146-0077E4E0-A39F-49D4-B8E5-1B65F6067458

Q37263146-008E549F-B5EC-4F32-9586-B3C68AB9E067

Q37263146-0218541B-1A0C-43C8-8F1A-53EBEFF1DCC5

Q37263146-02C37F19-E5C4-4B01-8A13-F01C8E9D6FEC

Q37263146-03E0C858-5664-41BB-9BF5-20693C86CB9B

Q37263146-058C0DE5-4E8F-4A98-A2EF-0B7259799804

Q37263146-07D0AA44-B6C4-4333-89E1-C07DF33DB71B

Q37263146-07E42C41-8F10-4467-B30D-C502331E8C81

Q37263146-08AF2177-26D6-4390-B691-D02D4B6DC3C7

Q37263146-093F648F-C957-43C3-AA89-6E8F3C086F32

P304

Q37263146-BFD71EFD-9CB1-4644-9CB4-F18ABD2C91AE

P31

Q37263146-B9C54C78-3255-47FE-B58C-DCDBA4F4F002

P356

Q37263146-DE43556B-5C8E-43FF-8FF2-EF53564CC421

P407

Q37263146-ED3F40CF-7B5C-4431-8E90-21B6B778D915

P433

Q37263146-DB1698A9-D152-47C3-A85C-AFE917F43EE3

P478

Q37263146-58C1DB08-A6A4-4C3B-871F-D3E34DC2BEB0

P50

Q37263146-117556BD-C923-486D-BD79-AE4E4F345D27

Q37263146-5E1FC480-F3D5-43B9-B010-00278AC9AD03

Q37263146-712481E6-1D4B-41D3-A59F-61BA5B9B3F29

Q37263146-BC271F73-F353-4F28-A373-1A84AE45120D

Q37263146-CCE4A4EF-7733-4810-8119-08B65516A107

P577

Q37263146-EC350476-30FD-4DA1-9695-7AA45E783453

P5875

Q37263146-318E5908-9141-4961-ADEC-77F0A3E290D6

P698

Q37263146-77D20985-F017-43D3-B0AA-9ED6E36C9274

P921

Q37263146-02122356-F309-46E8-8CEA-25D23D6D88C2

Q37263146-44fe3060-e92d-4b16-a94e-484a2af20ee3

P932

Q37263146-5248787A-791A-49E0-AEBC-6622A7861350

P356

BLOOD-2013-03-492884

P1433

P1476

Diagnosis and treatment of pri ...... from the European LeukemiaNet.

@en

P2093

Argiris Symeonidis

http://www.w3.org/2001/XMLSchema#string

Arjan A van de Loosdrecht

http://www.w3.org/2001/XMLSchema#string

Consuelo Del Cañizo

http://www.w3.org/2001/XMLSchema#string

David Bowen

http://www.w3.org/2001/XMLSchema#string

Dominik Selleslag

http://www.w3.org/2001/XMLSchema#string

European Leukemia Net

http://www.w3.org/2001/XMLSchema#string

Eva Hellström-Lindberg

http://www.w3.org/2001/XMLSchema#string

Ghulam Mufti

http://www.w3.org/2001/XMLSchema#string

Guillermo F Sanz

http://www.w3.org/2001/XMLSchema#string

Jaroslav Cermak

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Molecular pathogenesis and clinical management of Fanconi anemia

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

The World Health Organization (WHO) classification of the myeloid neoplasms

Proposals for the classification of the myelodysplastic syndromes

P304

2943-2964

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-03-492884

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Eva Hellström-Lindberg

Norbert Gattermann

Uwe Platzbecker

P577

2013-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256120318

http://www.w3.org/2001/XMLSchema#string

P698

23980065

http://www.w3.org/2001/XMLSchema#string

P921

P932

3811170

http://www.w3.org/2001/XMLSchema#string